Agilent exercises option to acquire remaining 52% in Lasergen for $105mm

22 Sep 2020

Agilent Technologies Inc. exercised its option to acquire the remaining 52% not already owned in Lasergen Inc. for $105mm.

In Vitro Diagnostics
Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Biotechnology
- Drug Discovery Tools
  - Genomics-Proteomics
  - Molecular Diversity

Acquisition
- Acquisition of Private Biotech
- Intra-Biotech Deal
- Partial Acquisition
- Payment Includes Cash

Already a Biomedtracker subscriber? You have access to the full deal record through your subscription

Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products.

Questions?

Please contact Sales at: (212) 520-2765 or email [email protected]

Related Companies

Agilent exercises option to acquire remaining 52% in Lasergen for $105mm

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

DCD.EmailPopout.Notice